Tenex Health Appoints Jay Hallinan as Chief Executive Officer

LAKE FOREST, Calif., Sept. 23, 2013 (GLOBE NEWSWIRE) -- Tenex Health
today announced that Jay Hallinan has been appointed as its new Chief
Executive Officer effective October 21, 2013. Chairman of the Board
Ivan Mijatovic said of the appointment, "Jay brings the global sales
and marketing experience to aggressively expand our current commercial
channels with a disciplined focus on execution. This approach is
critical for the expansion of current and future commercial

Prior to accepting the CEO role at Tenex Health, Mr. Hallinan served in
a senior executive sales position at Stryker Neurovascular. In that
position, he was responsible for managing over $200 million in annual
revenue. Additionally, Mr. Hallinan has held a number of leadership
positions with 3M, Medtronic, and Boston Scientific.

Mr. Hallinan characterized the opportunity by saying, "Tenex Health is
at an exciting point in its evolution as a company. The company has
successfully proven the clinical and commercial viability of its
innovative technology. Hundreds of U.S. physicians have successfully
treated over 8,000 patients and the TX1 system is now cleared to sell
in most major markets around the world."

Tenex Health's current CEO and Founder Jagi Gill, PhD will remain with
the company and assume the role of Chief Scientific Officer. In this
role Dr. Gill will work to leverage the technology platform and build a
robust product portfolio. He will also remain on the Board of
Directors. Dr. Gill said of Hallinan's appointment, "The Board has
appointed a new CEO with significant experience in commercializing
medical devices and I am excited to work with him to optimize our
global opportunities. Our technology and organization are ready to take
full advantage of those capabilities."

Mr. Hallinan is a graduate of the University of Georgia and received
his M.B.A. from the McColl School of Business at Queens College.

About Tenex Health, Inc.

Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com)
develops and markets innovative therapies for the treatment of tendon
pain due to trauma or repetitive motion injuries. The minimally
invasive technique utilizes the company's proprietary TX MicroTip(TM)
handpiece to cut and debride diseased tissue in an outpatient setting
in under 20 minutes, using only a local anesthetic. Since the
surrounding healthy tendon tissue is not disturbed, patients enjoy less
discomfort and faster recovery times versus traditional open surgical

CONTACT: Tenex Health, Inc.
         MaryAnn Tingley
         Vice-President of Marketing
         949-454-7500 x 245

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.